Welcome to our dedicated page for Picard Medical SEC filings (Ticker: PMI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This Picard Medical, Inc. (PMI) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Picard Medical is a Delaware corporation listed on the NYSE American, and its filings describe a business conducted through SynCardia Systems, LLC, a medical technology company that manufactures and sells the SynCardia Total Artificial Heart (STAH) for patients with advanced heart failure.
Through documents such as Form S-1 registration statements and Form 8-K current reports, investors can review detailed information about Picard Medical’s operations, financing arrangements, and risk factors. The S-1 filing explains that SynCardia’s platform includes the SynCardia 50cc and 70cc total artificial hearts, external drivers, ancillary hardware, and associated surgeon and center training. It also notes that the company’s customers are major medical centers operating heart transplant and mechanical circulatory support programs and that SynCardia operates an ISO 13485–certified quality management system.
Form 8-K filings for Picard Medical include disclosures on material definitive agreements, such as senior secured notes and warrant financings, bridge financing arrangements, and related security agreements. Additional 8-Ks furnish press releases and presentation materials related to clinical and technical updates on the next-generation, fully implantable Emperor Total Artificial Heart, as well as corporate events like conference presentations and exchange bell-ringing ceremonies.
On this page, users can follow real-time updates from EDGAR and use AI-powered summaries to understand the key points in lengthy filings. Forms such as the S-1, 8-K, and any future 10-K annual reports, 10-Q quarterly reports, or proxy statements can provide insight into Picard Medical’s capital structure, governance, risk profile, and the progress of its SynCardia and Emperor total artificial heart platforms. Insider transaction reports on Form 4, when available, can also be reviewed to see changes in beneficial ownership by company insiders.
Bernard Skaggs, Chief Financial Officer of Picard Medical, Inc. (PMI), filed an amended Form 3 reporting two employee stock option awards. The filing shows 102,239 options granted with a $0.71 exercise price (as adjusted) and 408,956 options granted with a $0.71 exercise price (as adjusted). Each grant has a vesting commencement date (first: February 21, 2023; second: November 27, 2023). For both grants one-quarter cliff vests on the first anniversary of the vesting commencement date, with the remainder vesting monthly over the following 36 months, subject to continued service. The exercise price and share amounts were adjusted to reflect a combined forward and reverse split resulting in an overall forward split of 1 for 2.1524. The form was signed by Emily Semon as attorney-in-fact on 08/28/2025.
Picard Medical, Inc. (PMI) reporting person Matt Schuster filed an amended Form 3 disclosing employee stock options granted on June 28, 2024. The filing shows three option awards underlying common stock: 102,239, 408,956, and 68,608 shares, each with an exercise price adjusted to $0.71 after an overall forward split of 1 for 2.1524. Vesting for each award began in 2023 with a one-quarter cliff at the first anniversary and remaining amounts vesting monthly over the following 36 months, subject to continued service. The amendment corrects the conversion/exercise price to reflect the stock split.
Picard Medical, Inc. reporting person Patrick Schnegelsberg, identified as both a director and the company's Chief Executive Officer, filed an amended Form 3 to report equity derivative holdings. The amendment corrects the conversion/exercise price to reflect a combined 1 for 2.1524 forward stock split adjustment (a 1 for 2.2 forward split followed by a 1.0221 for 1 reverse split). The filing shows 2,378,124 employee stock options underlying common stock with an exercise price of $0.71 (as adjusted). The options were granted June 28, 2024, with a vesting commencement date of July 5, 2023: one quarter cliff vested on the first anniversary and the remainder vests monthly over the subsequent 36 months, subject to continued service. The Form 3/A is signed by an attorney-in-fact on behalf of the reporting person.